Abstracts tagged "Japanese"

Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Mitsuhiro Takeno¹, Yoshiya Tanaka², Hajime Kono³, Shouji Sugii⁴, Mitsumasa Kishimoto⁵, Sue Cheng⁶, Shannon McCue⁶, Maria Paris⁶ and Hiroaki Dobashi⁷, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶Celgene Corporation, Summit, NJ, ⁷Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
Abstract Number: 431 • 2017 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
Tsuneyo Mimori¹, Masayoshi Harigai², Tatsuya Atsumi³, Masataka Kuwana⁴, Syuji Takei⁵, Naoto Tamura⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Takeshi Kokubo¹¹, Yutaka Endo¹¹, Naonobu Sugiyama¹¹, Tomohiro Hirose¹¹, Yosuke Morishima¹¹ and Noritoshi Yoshii¹¹, ¹Kyoto University, Kyoto, Japan, ²Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Nippon Medical School, Tokyo, Japan, ⁵Kagoshima University, Kagoshima, Japan, ⁶Juntendo University, Tokyo, Japan, ⁷Wakayama Medical University, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰University of Tokyo, Tokyo, Japan, ¹¹Pfizer Japan Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients…
Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…
Abstract Number: 1165 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan
Dai Kishida¹, Masahide Yazaki¹, Akinori Nakamura¹, Ayako Tsuchiya-Suzuki¹, Yasuhiro Shimojima² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever and polyserositis. Most patients have their first febrile attack before…
Abstract Number: 1343 • 2017 ACR/ARHP Annual Meeting
Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Takefumi Furuya¹, Eisuke Inoue², Shigeru Maeda³, Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ³Department of Dental Anesthesiology, Okayama University Hospital, Okayama, Japan
Background/Purpose: Oral health is an important issue for patients with rheumatoid arthritis (RA) because periodontitis is a potential risk factor for RA and RA patients…
Abstract Number: 2588 • 2017 ACR/ARHP Annual Meeting
Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Tomofumi Kiyokawa¹, Hironari Hanaoka², Harunobu Iida¹, Yukiko Takakuwa¹ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine,, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: The guideline or recommendation for lupus nephritis (LN) has been recently established by both ACR and EULAR, and hydroxychloriquine (HCQ) is recommended for all…
Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Takefumi Furuya¹, Eisuke Inoue^1,2, Masanori Nakayama¹, Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima³, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Naoki Agata⁵ and Tsutomu Takeuchi⁶, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie GK, Tokyo, Japan, ⁶Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Yoshiya Tanaka¹, Kiyotaka Yamazaki², Ryo Nakajima², Shuichi Komatsu³, Naoki Agata⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Communication, Medical, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…
Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting
Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…
Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].